Zacks Research Has Bullish Estimate for Stryker Q1 Earnings

Stryker Co. (NYSE:SYK) – Stock analysts at Zacks Research upped their Q1 2025 earnings estimates for Stryker in a research report issued on Monday, November 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical technology company will post earnings of $2.82 per share for the quarter, up from their prior forecast of $2.74. The consensus estimate for Stryker’s current full-year earnings is $12.06 per share. Zacks Research also issued estimates for Stryker’s Q3 2025 earnings at $3.26 EPS, Q4 2025 earnings at $4.23 EPS and FY2025 earnings at $13.53 EPS.

A number of other analysts have also issued reports on SYK. Wolfe Research initiated coverage on Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. Needham & Company LLC increased their target price on shares of Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Evercore ISI upped their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group increased their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Stifel Nicolaus lowered their target price on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Price Performance

Stryker stock opened at $384.88 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company’s fifty day moving average price is $366.20 and its 200 day moving average price is $349.36. The stock has a market capitalization of $146.72 billion, a P/E ratio of 41.25, a P/E/G ratio of 2.93 and a beta of 0.91. Stryker has a 1 year low of $285.79 and a 1 year high of $398.20.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.46 earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Dunhill Financial LLC boosted its position in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Centennial Bank AR lifted its stake in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Stryker during the 3rd quarter worth about $36,000. HBW Advisory Services LLC purchased a new position in shares of Stryker during the third quarter valued at approximately $42,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker during the third quarter worth $42,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 600 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 67,381 shares of company stock valued at $24,825,275 in the last ninety days. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.